Adeia targets $600M long-term annual revenue as semiconductor opportunity rises to $200M (NASDAQ:ADEA)
Adeia (ADEA) Q2 2026 earnings call recap: $96.1M revenue, 58.7% EBITDA margin, raised $600M target, licensing wins, litigation risksâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.

Adeia (ADEA) Q2 2026 earnings call recap: $96.1M revenue, 58.7% EBITDA margin, raised $600M target, licensing wins, litigation risksâread now.
Adeia targets $600M long-term annual revenue as semiconductor opportunity rises to $200M (NASDAQ:ADEA) | Seeking Alpha
Earnings Call Insights: Adeia (ADEA) Q2 2026
Management View
"Our second quarter results were in line with our expectations as we delivered revenue of $96.1 million with an adjusted EBITDA margin of 58.7%." (CEO & Director Paul Davis)
"I am
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
How does increased semiconductor market exposure affect Adeia's growth outlook?
Management significantly raised the semiconductor revenue target from $100 million to $200 million annually and reported strong semiconductor pipeline momentum, indicating increasing exposure is a central driver of long-term growth.
What are the main risks associated with Adeiaâs revenue targets, including litigation and deal timing?
Management emphasized revenue sensitivity to the timing of license deals and litigation outcomes, especially in Pay-TV. Ongoing and new legal actions, like against Fubo, can lead to short-term revenue volatility.
How sustainable is Adeiaâs recurring revenue mix outside of Pay-TV?
Management highlighted ongoing growth in non-Pay-TV recurring revenue and sees continued positive trends as the impacts from Pay-TV contract losses diminish.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
V2X Beats 2026 Revenue Guidance, Targets Net Leverage of 2x by Year-End
V2X projects 2026 revenue of $4.875-$5.025 billion and plans to cut net leverage to ~2x by year-end. Explore its growth drivers, deleveraging path, and industry backdrop.

Ichor anticipates Q3 revenue of $315M-$345M with gross margin of 14.5%-15.5% as second-half volumes target at least 25% above first half (NASDAQ:ICHR)
Ichor (ICHR) Q2 2026 earnings call: Q3 guidance, margin expansion, $3B capacity plans, ATM funding, and supply-chain risksâread key takeaways now.

TotalEnergies Subsidiary Hutchinson Secures $191.6M U.S. Army Tire Contract, Advancing Diversification Strategy
TotalEnergies' subsidiary Hutchinson has been awarded a U.S. Army contract worth up to $191.6 million for wheel and tire assemblies, bolstering its defense supply chain position and supporting the company's diversification strategy. The deal underscores the growing demand for military vehicle components amid global geopolitical tensions.

ORIC Pharmaceuticals GAAP EPS of -$0.38 misses by $0.02 (ORIC:NASDAQ)
ORIC Pharmaceuticals (ORIC) Q2 GAAP EPS -$0.38 misses by $0.02; cash/investments $387.6M funds operations into 2H 2028.
